

# The best start for a new life

CultureScience  
Clinically Tested



Infant colic is a common condition, affecting around 25% of babies under three months. While temporary, it often leads to prolonged crying and discomfort, disrupting sleep and creating stress for both infants and parents during the first weeks of life.

Scientific evidence highlights the importance of the mum–baby axis, the close connection between maternal health and infant well-being, particularly through the microbiota. A balanced maternal microbiome during pregnancy influences the baby's gut health, immune system, and overall comfort after

birth. Because probiotics need time to establish their protective function, maternal supplementation in the last trimester is the most effective way to prepare the infant gut for a healthy start and reduce colic risk.

LR92 is the first probiotic **clinically proven to reduce the incidence of infant colic** when taken by mothers during late pregnancy, offering a natural, science-backed solution for infant comfort, parental peace of mind, and a healthier beginning for family life.



### Unique Prenatal-Proven Colic Solution

LR92 is the first and only probiotic clinically validated to reduce infant colic when taken during the last trimester of pregnancy, delivering unmatched differentiation for brands seeking unique maternal–infant wellness positioning.



### Effective from Birth

Administered in the last trimester, LR92 begins working before birth, ensuring immediate benefits for the newborn's gut health and well-being.



### C-Section Infant Support

C-section delivery is linked to microbiota imbalance and reduced beneficial bacteria. LR92 provides significant advantages even for babies delivered via C-section, supporting early microbiome balance from day one.



### Low-Dose, High-Efficacy

With a minimal daily dose of 0,1 billion CFU, LR92 offers robust protection from birth, fitting into prenatal blends without altering formulation dynamics.

VEGETARIAN

HYPOALLERGENIC

HALAL

GMO FREE

GLUTEN FREE

KOSHER

## How LR92 reduces colics

LR92 supports infant comfort through a multi-action approach that begins during pregnancy. Clinical evidence suggests that prenatal supplementation can help reduce the risk of colic, possibly by affecting key maternal and infant pathways.

LR92 may promote the **production of anti-inflammatory mediators**, such as IL-10 and TGF- $\beta$ , in breast milk, **supporting gut maturation**, enhancing IgA secretion, and improving overall gastrointestinal function. It also **reinforces the intestinal barrier** by stabilizing tight


junctions and boosting mucin production—critical for a resilient gut environment.

Beyond these effects, LR92 may **stimulate the synthesis of GABA**, the main inhibitory neurotransmitter involved in regulating behavior and discomfort perception, while positively shaping the early development of the infant's gut microbiota. Together, these mechanisms help create a balanced gut ecosystem and reduce the likelihood of colic from the very first days of life.


## LR92 clinical evidence

**145 Pregnant Women**      **0,1 Bn CFU/DAY**      **90 Days Treatment Time**


### Infants free from colic



### Demonstrated protective efficacy in C-section infants



### Distribution and Mean Severity of Infant Colic



\*statistically significant difference

[1] Zeevenhooven J, et al., Nat Rev Gastroenterol Hepatol 15(8):479-496 (2018) [2] <https://www.mayoclinic.org/diseases-conditions/colic/symptoms-causes/syc-20371074> [3] Sung V, et al., BMC Pediatr 12:135 (2012) [4] Pérez-Castillo ÍM, et al., Nutrients 17;13(1):256 (2021) [5] Pourmirzaiee MA, et al., Eur J Pediatr 179, 1619-1626 (2020)

This information is intended for business to business and Healthcare professionals' communication for specific ingredients for food, beverage, and supplement producers. The statements and information contained herein are not intended for final consumers of finished products. Any claims made for consumers remains the sole responsibility of the marketer of the finished product. This information is provided "as is" and its use is at the recipient's sole discretion and risk. The statements made within this information have not been evaluated by the Food and Drug Administration. These statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. Each of the names of the products, ideas, brands, trademarks and logos mentioned in this document, however presented (i.e. displaying the ® or TM symbol, written in bold or large print, etc.), are either property of SaccoSystem, owned by an affiliate or covered by a licensing agreement. What is presented in this document as a trademark may not be such in your specific country, notwithstanding the potential presence of the ® symbol, due to national registration regulations and processes.